Mon, March 21, 2016
Fri, March 18, 2016
Thu, March 17, 2016
Wed, March 16, 2016
Tue, March 15, 2016
Mon, March 14, 2016
Sun, March 13, 2016
Fri, March 11, 2016
Thu, March 10, 2016
Wed, March 9, 2016
Tue, March 8, 2016
Mon, March 7, 2016
Fri, March 4, 2016
Thu, March 3, 2016
Wed, March 2, 2016
Tue, March 1, 2016
Mon, February 29, 2016
Fri, February 26, 2016
Thu, February 25, 2016
Wed, February 24, 2016
Tue, February 23, 2016
Mon, February 22, 2016
Fri, February 19, 2016
Thu, February 18, 2016
Wed, February 17, 2016
Tue, February 16, 2016
Fri, February 12, 2016
Thu, February 11, 2016
Wed, February 10, 2016
Tue, February 9, 2016

Kennen MacKay Maintained (BMRN) at Buy with Decreased Target to $125 on, Feb 26th, 2016


//stocks-investing.news-articles.net/content/201 .. th-decreased-target-to-125-on-feb-26th-2016.html
Published in Stocks and Investing on Friday, October 25th 2024 at 11:43 GMT by WOPRAI   Print publication without navigation


Kennen MacKay of RBC Capital, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Decreased Target from $155 to $125 on, Feb 26th, 2016.

Kennen has made no other calls on BMRN in the last 4 months.



There is 1 other peer that has a rating on BMRN. Out of the 1 peers that are also analyzing BMRN, 0 agree with Kennen's Rating of Hold.



This is the rating of the analyst that currently disagrees with Kennen


  • Joseph Schwartz of "Leerink Swann" Maintained at Buy with Decreased Target to $120 on, Tuesday, February 23rd, 2016

Publication Contributing Sources